Ligand Pharmaceuticals Future Growth
Future criteria checks 4/6
Ligand Pharmaceuticals is forecast to grow earnings and revenue by 26.9% and 16% per annum respectively while EPS is expected to grow by 23.3% per annum.
Key information
26.9%
Earnings growth rate
23.3%
EPS growth rate
Pharmaceuticals earnings growth | 19.6% |
Revenue growth rate | 16.0% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 23 Dec 2024 |
Recent future growth updates
Recent updates
Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
Nov 24Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings
Oct 31Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 260 | 101 | 109 | N/A | 2 |
12/31/2026 | 222 | 96 | 91 | 171 | 4 |
12/31/2025 | 189 | 64 | 60 | 126 | 7 |
12/31/2024 | 163 | 34 | 22 | 84 | 7 |
9/30/2024 | 152 | 45 | 25 | 77 | N/A |
6/30/2024 | 133 | 42 | -4 | 48 | N/A |
3/31/2024 | 118 | 96 | -17 | 34 | N/A |
12/31/2023 | 131 | 54 | -4 | 50 | N/A |
9/30/2023 | 154 | 21 | 90 | 95 | N/A |
6/30/2023 | 180 | 41 | 99 | 108 | N/A |
3/31/2023 | 204 | 51 | 104 | 120 | N/A |
12/31/2022 | 196 | -5 | 120 | 138 | N/A |
9/30/2022 | 183 | 23 | 95 | 112 | N/A |
6/30/2022 | 188 | 27 | 97 | 112 | N/A |
3/31/2022 | 223 | 45 | 110 | 120 | N/A |
12/31/2021 | 242 | 76 | 71 | 79 | N/A |
9/30/2021 | 275 | 68 | 45 | 52 | N/A |
6/30/2021 | 252 | 48 | 37 | 44 | N/A |
3/31/2021 | 208 | 39 | 42 | 48 | N/A |
12/31/2020 | 164 | 7 | 51 | 55 | N/A |
9/30/2020 | 143 | -16 | 41 | 47 | N/A |
6/30/2020 | 126 | -25 | 24 | 28 | N/A |
3/31/2020 | 110 | -61 | -60 | -58 | N/A |
12/31/2019 | 120 | 629 | 781 | -29 | N/A |
9/30/2019 | 153 | 594 | 812 | 11 | N/A |
6/30/2019 | 174 | 677 | 846 | 44 | N/A |
3/31/2019 | 239 | 764 | 980 | 179 | N/A |
12/31/2018 | 251 | 143 | 183 | 194 | N/A |
9/30/2018 | 242 | 179 | 198 | 193 | N/A |
6/30/2018 | 230 | 120 | N/A | 193 | N/A |
3/31/2018 | 168 | 53 | N/A | 130 | N/A |
12/31/2017 | 141 | 13 | N/A | 89 | N/A |
9/30/2017 | 129 | 16 | N/A | 78 | N/A |
6/30/2017 | 117 | 9 | N/A | 69 | N/A |
3/31/2017 | 109 | -3 | N/A | 69 | N/A |
12/31/2016 | 109 | -2 | N/A | 61 | N/A |
9/30/2016 | 92 | 7 | N/A | 56 | N/A |
6/30/2016 | 88 | 205 | N/A | 48 | N/A |
3/31/2016 | 87 | 235 | N/A | 47 | N/A |
12/31/2015 | 72 | 230 | N/A | 42 | N/A |
9/30/2015 | 74 | 231 | N/A | 38 | N/A |
6/30/2015 | 71 | 33 | N/A | 32 | N/A |
3/31/2015 | 63 | 11 | N/A | 26 | N/A |
12/31/2014 | 65 | 12 | N/A | 21 | N/A |
9/30/2014 | 56 | 7 | N/A | 22 | N/A |
6/30/2014 | 54 | 8 | N/A | 18 | N/A |
3/31/2014 | 53 | 10 | N/A | 21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LGND's forecast earnings growth (26.9% per year) is above the savings rate (2.6%).
Earnings vs Market: LGND's earnings (26.9% per year) are forecast to grow faster than the US market (15.1% per year).
High Growth Earnings: LGND's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: LGND's revenue (16% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: LGND's revenue (16% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LGND's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/08 02:46 |
End of Day Share Price | 2025/01/08 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ligand Pharmaceuticals Incorporated is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jasper Hellweg | Argus Research Company |
Balaji Prasad | Barclays |
Balaji Prasad | Barclays |